Skip to Main content Skip to Navigation
Journal articles

Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells

Abstract : The HVEM (TNFRSF14) receptor gene is among the most frequently mutated genes in germinal center lymphomas. We report that loss of HVEM leads to cell-autonomous activation of B cell proliferation and drives the development of GC lymphomas in vivo. HVEM-deficient lymphoma B cells also induce a tumor-supportive microenvironment marked by exacerbated lymphoid stroma activation and increased recruitment of T follicular helper (T-FH) cells. These changes result from the disruption of inhibitory cell-cell interactions between the HVEM and BTLA (B and T lymphocyte attenuator) receptors. Accordingly, administration of the HVEM ectodomain protein (solHVEM ((P37-V202))) binds BTLA and restores tumor suppression. To deliver solHVEM to lymphomas in vivo, we engineered CD19-targeted chimeric antigen receptor (CAR) T cells that produce solHVEM locally and continuously. These modified CAR-T cells show enhanced therapeutic activity against xenografted lymphomas. Hence, the HVEM-BTLA axis opposes lymphoma development, and our study illustrates the use of CAR-T cells as "micro-pharmacies'' able to deliver an anti-cancer protein.
Document type :
Journal articles
Complete list of metadata
Contributor : Xavier Chard-Hutchinson <>
Submitted on : Wednesday, November 30, 2016 - 3:30:17 PM
Last modification on : Thursday, January 14, 2021 - 11:29:56 AM

Links full text



Michael Boice, Darin Salloum, Frédéric Mourcin, Viraj Sanghvi, Rada Amin, et al.. Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells. Cell, Elsevier, 2016, 167 (2), pp.405-418 e13. ⟨10.1016/j.cell.2016.08.032⟩. ⟨hal-01405853⟩



Record views